Get the Stockscreener App
1.83
5.78%
0.10
Pre-market:
1.83
Inmune Bio Inc stock is traded at $1.83, with a volume of 505.17K.
It is up +5.78% in the last 24 hours and down -11.59% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$1.73
Open:
$1.75
24h Volume:
505.17K
Relative Volume:
0.52
Market Cap:
$48.65M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-1.0958
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
-3.68%
1M Performance:
-11.59%
6M Performance:
-76.72%
1Y Performance:
-68.72%
1-Day Range:
$1.75
$1.9262
1-Week Range:
$1.73
$1.95
52-Week Range:
$1.71
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.83 | 45.99M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Earnings visualization tools for INmune Bio Inc.Rate Cut & Safe Entry Point Identification - newser.com
Published on: 2025-11-02 21:20:18 - newser.com
Published on: 2025-11-02 20:37:16 - newser.com
Inmune Bio Reports Q3 2025 Financial Results - MSN
How INmune Bio Inc. stock reacts to Fed rate cutsPortfolio Gains Summary & Safe Entry Momentum Stock Tips - newser.com
Statistical indicators supporting INmune Bio Inc.’s strengthMarket Activity Summary & Fast Exit/Entry Strategy Plans - newser.com
What makes INmune Bio Inc. stock attractive to growth fundsMarket Movers & Long-Term Growth Plans - newser.com
Short interest data insights for INmune Bio Inc.Earnings Growth Summary & Stock Portfolio Risk Control - newser.com
Sentiment analysis tools applied to INmune Bio Inc.Breakout Watch & Risk Controlled Stock Pick Alerts - newser.com
INmune Bio, Inc. (NASDAQ:INMB) Q3 2025 Earnings Call Transcript - Insider Monkey
Will INmune Bio Inc. stock outperform tech sector in 2025Treasury Yields & Daily Chart Pattern Signal Reports - newser.com
Inmune Bio to Host Q3 Results Conference Call - MSN
What analysts say about INmune Bio Inc stockMarket Liquidity Analysis & High Return Trading Ideas - earlytimes.in
How INmune Bio Inc. stock benefits from global expansionJuly 2025 PostEarnings & Safe Entry Trade Reports - newser.com
Candlestick signals on INmune Bio Inc. stock todayWeekly Trading Summary & AI Optimized Trade Strategies - newser.com
Sector ETF performance correlation with INmune Bio Inc.July 2025 Trends & AI Driven Price Forecasts - newser.com
Can volume confirm reversal in INmune Bio Inc.July 2025 Volume & Fast Moving Market Watchlists - newser.com
Earnings call transcript: INmune Bio beats Q3 2025 EPS forecast, stock dips - Investing.com Australia
Earnings call transcript: INmune Bio beats Q3 2025 EPS forecast, stock dips By Investing.com - Investing.com South Africa
Is INmune Bio Inc. stock overvalued by current metricsRisk Management & Daily Growth Stock Tips - newser.com
Inmune Bio outlines 2026 regulatory milestones and cash runway through Q4 2026 - MSN
Is it time to cut losses on INmune Bio Inc.Weekly Trade Report & Weekly Breakout Opportunity Watchlist - newser.com
Transcript : INmune Bio, Inc., Q3 2025 Earnings Call, Oct 30, 2025 - MarketScreener
INmune Bio Inc (INMB) Q3 2025 Earnings Call Highlights: Regulatory Progress and Financial ... - Yahoo Finance
INmune Bio Inc (INMB) Q3 2025 Earnings Call Highlights: Regulato - GuruFocus
INmune Bio Shrinks Losses While Analysts See Upside Ahead - Finimize
INMB Maintains Strong Cash Position with $27.7 Million on Hand - GuruFocus
INmune Bio Q3 net loss narrows to $6.5 mln, names new CEO - MarketScreener
[8-K] Inmune Bio, Inc. Reports Material Event | INMB SEC FilingForm 8-K - Stock Titan
INmune Bio Inc. (INMB) Q3 FY2025 earnings call transcript - Yahoo Finance
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update - The Manila Times
INmune Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
INMB posts Q3 loss and $16,514,000 impairment amid XPro setback - Stock Titan
Analyzing recovery setups for INmune Bio Inc. investorsWeekly Stock Summary & Daily Volume Surge Signals - newser.com
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):